Global trends and epidemiological shifts in gastrointestinal cancers: insights from the past four decades

Abstract

Background: The epidemiological profiles of gastrointestinal (GI) cancers vary across countries and over time, largely reflecting variations in risk factors and screening practices. We aimed to provide an overview of the current global burden of the five major types of GI cancers and conduct an updated evaluation of the long-term trends of GI cancers.

Methods: The updated numbers of new cases and deaths, and age-standardized rates (ASR), of the five GI cancers for 185 countries were sourced from the GLOBOCAN 2022, and presented by cancer site, continent, and human development index (HDI). For 43 countries, annual incidence and mortality data were obtained from the Cancer Incidence in Five Continents Plus and World Health Organization mortality databases, supplemented by the mortality data from the Disease Surveillance Points system for China. We compared the long-term trends of ASRs across countries since 1980, and estimated average annual percent changes (AAPCs) for the recent period 2003-2017.

Results: In 2022, there were 4,783,391 new cases and 3,235,719 deaths from the five GI cancers, accounting for 23.9% and 33.2% of all new cancer cases and deaths worldwide, respectively. Cancers of oesophagus, stomach, and liver were more common in Asian and high HDI countries, and colorectal and pancreatic cancer in western and very high HDI countries. Downward trends were observed in almost all countries for gastric cancer and most countries for oesophageal cancer. For colorectal cancer, the most favorable and unfavorable trends were found in 10 and 19 countries respectively. The largest decreases in liver cancer burden were mainly in eastern and southeastern Asia, while increases were seen in North America, Oceania, and Northern Europe, with AAPCs of 3%∼7% for incidence and 2%∼9% for mortality during 2003-2017. Half of the included countries showed increases in pancreatic cancer burden, with the largest AAPCs in Cyprus, Thailand, India,Türkiye, France, and Belarus for incidence, and Türkiye, Thailand, and China for mortality.

Conclusions: Deviating patterns were found for GI cancers worldwide. Multi-setting studies might provide insights into the underlying etiologies of these cancers, and identify areas where urgent cancer control strategies are needed.

Keywords

colorectal cancer / epidemiology / gastric cancer / gastrointestinal cancer / global burden / liver cancer / oesophageal cancer / pancreatic cancer / time trend

References

[1] Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3): 229-63.

[2] Diao X, Guo C, Jin Y, Li B, Gao X, Du X, et al. Cancer situation in China: an analysis based on the global epidemiological data released in 2024. Cancer Commun (Lond). 2025; 45(2): 178-97.

[3] Islami F, Marlow EC, Thomson B, McCullough ML, Rumgay H, Gapstur SM, et al. Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, 2019. CA Cancer J Clin. 2024; 74(5): 405-32.

[4] Abnet CC, Corley DA, Freedman ND, Kamangar F. Diet and upper gastrointestinal malignancies. Gastroenterology. 2015; 148(6): 1234-43. e4.

[5] Lagergren J, Andersson G, Talbäck M, Drefahl S, Bihagen E, Härkönen J, et al. Marital status, education, and income in relation to the risk of esophageal and gastric cancer by histological type and site. Cancer. 2016; 122(2): 207-12.

[6] Tu Z, Liao S, Chen C, Li C, Hu Q, Cai C, et al. The long-term spatiotemporal trends in lung cancer burden and its risk factors at global, regional, and national levels, 1992-2021: The Global Burden of Disease Study 2021. Cancer Commun (Lond). 2024; 44(12): 1418-21.

[7] Arnold M, Abnet CC, Neale RE, Vignat J, Giovannucci EL, McGlynn KA, et al. Global Burden of 5 Major Types of Gastrointestinal Cancer. Gastroenterology. 2020; 159(1): 335-49. e15.

[8] Jun JK, Choi KS, Lee HY, Suh M, Park B, Song SH, et al. Effectiveness of the Korean National Cancer Screening Program in Reducing Gastric Cancer Mortality. Gastroenterology. 2017; 152(6): 1319-28. e7.

[9] Nishihara R, Wu K, Lochhead P, Morikawa T, Liao X, Qian ZR, et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med. 2013; 369(12): 1095-105.

[10] Wei WQ, Chen ZF, He YT, Feng H, Hou J, Lin DM, et al. Long-Term Follow-Up of a Community Assignment, One-Time Endoscopic Screening Study of Esophageal Cancer in China. J Clin Oncol. 2015; 33(17): 1951-7.

[11] Schreuders EH, Ruco A, Rabeneck L, Schoen RE, Sung JJ, Young GP, et al. Colorectal cancer screening: a global overview of existing programmes. Gut. 2015; 64(10): 1637-49.

[12] Wee HL, Canfell K, Chiu HM, Choi KS, Cox B, Bhoo-Pathy N, et al. Cancer screening programs in South-east Asia and Western Pacific. BMC Health Serv Res. 2024; 24(1): 102.

[13] Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today (version 1.1). Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.who.int/today. Accessed 9/12/2024.

[14] Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021; 149(4): 778-89.

[15] Segi M. Cancer mortality for selected sites in 24 countries (1950-57). 1960. Available from: https://www.scienceopen.com/document?vid=d36053cb-ebfe-4b4c-a7ca-05447aa3cd19

[16] Li M, Dal Maso L, Pizzato M, Vaccarella S. Evolving epidemiological patterns of thyroid cancer and estimates of overdiagnosis in 2013-17 in 63 countries worldwide: a population-based study. Lancet Diabetes Endocrinol. 2024; 12(11): 824-36.

[17] World Health Organization Mortality Database. Accessed 5/3/2024. Available at https://www.who.int/data/data-collection-tools/who-mortality-database

[18] United Nations Development Programme. Accessed 6/2/2024. Available at https://hdr.undp.org/data-center/human-development-index#/indicies/HDI

[19] WHO Data Platform. WHO Mortality Database. Data usability: completeness and proportion of ill-defined or non-specific causes. Accessed 27/02/2024. Available https://platform.who.int/mortality/about/data-quality

[20] China CDC. Disease Surveillance Points system. Access 26/11/2024. https://ncncd.chinacdc.cn/jcysj/siyinjcx/syfxbg/

[21] Liu S, Wu X, Lopez AD, Wang L, Cai Y, Page A, et al. An integrated national mortality surveillance system for death registration and mortality surveillance, China. Bull World Health Organ. 2016; 94(1): 46-57.

[22] Vaccarella S, Li M, Bray F, Kvale R, Serraino D, Lorenzoni V, et al. Prostate cancer incidence and mortality in Europe and implications for screening activities: population based study. Bmj. 2024; 386: e077738.

[23] Morgan E, Soerjomataram I, Rumgay H, Coleman HG, Thrift AP, Vignat J, et al. The Global Landscape of Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma Incidence and Mortality in 2020 and Projections to 2040: New Estimates From GLOBOCAN 2020. Gastroenterology. 2022; 163(3): 649-58. e2.

[24] Li M, Park JY, Sheikh M, Kayamba V, Rumgay H, Jenab M, et al. Population-based investigation of common and deviating patterns of gastric cancer and oesophageal cancer incidence across populations and time. Gut. 2023; 72(5): 846-54.

[25] Sheikh M, Roshandel G, McCormack V, Malekzadeh R. Current Status and Future Prospects for Esophageal Cancer. Cancers (Basel). 2023; 15(3): 765.

[26] McCormack VA, Menya D, Munishi MO, Dzamalala C, Gasmelseed N, Leon Roux M, et al. Informing etiologic research priorities for squamous cell esophageal cancer in Africa: A review of setting-specific exposures to known and putative risk factors. Int J Cancer. 2017; 140(2): 259-71.

[27] Kamangar F, Nasrollahzadeh D, Safiri S, Sepanlou SG, Fitzmaurice C, Ikuta KS, et al. The global, regional, and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020; 5(6): 582-97.

[28] Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet. 2024; 403(10431): 1027-50.

[29] An L, Zheng R, Zeng H, Zhang S, Chen R, Wang S, et al. The survival of esophageal cancer by subtype in China with comparison to the United States. Int J Cancer. 2023; 152(2): 151-61.

[30] Sonnenberg A. Differences in the birth-cohort patterns of gastric cancer and peptic ulcer. Gut. 2010; 59(6): 736-43.

[31] Howson CP, Hiyama T, Wynder EL. The decline in gastric cancer: epidemiology of an unplanned triumph. Epidemiol Rev. 1986; 8: 1-27.

[32] Arnold M, Park JY, Camargo MC, Lunet N, Forman D, Soerjomataram I. Is gastric cancer becoming a rare disease? A global assessment of predicted incidence trends to 2035. Gut. 2020; 69(5): 823-9.

[33] de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 2020; 8(2): e180-e90.

[34] Yang L, Kartsonaki C, Yao P, de Martel C, Plummer M, Chapman D, et al. The relative and attributable risks of cardia and non-cardia gastric cancer associated with Helicobacter pylori infection in China: a case-cohort study. Lancet Public Health. 2021; 6(12): e888-e96.

[35] Chen YC, Malfertheiner P, Yu HT, Kuo CL, Chang YY, Meng FT, et al. Global Prevalence of Helicobacter pylori Infection and Incidence of Gastric Cancer Between 1980 and 2022. Gastroenterology. 2024; 166(4): 605-19.

[36] Li M, Sun Y, Yang J, de Martel C, Charvat H, Clifford GM, et al. Time trends and other sources of variation in Helicobacter pylori infection in mainland China: A systematic review and meta-analysis. Helicobacter. 2020; 25(5): e12729.

[37] Fan X, Qin X, Zhang Y, Li Z, Zhou T, Zhang J, et al. Screening for gastric cancer in China: Advances, challenges and visions. Chin J Cancer Res. 2021; 33(2): 168-80.

[38] Murphy CC, Zaki TA. Changing epidemiology of colorectal cancer - birth cohort effects and emerging risk factors. Nat Rev Gastroenterol Hepatol. 2024; 21(1): 25-34.

[39] Sinicrope FA. Increasing Incidence of Early-Onset Colorectal Cancer. N Engl J Med. 2022; 386(16): 1547-58.

[40] Mandel JS, Church TR, Bond JH, Ederer F, Geisser MS, Mongin SJ, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med. 2000; 343(22): 1603-7.

[41] Blom J, Saraste D, Törnberg S, Jonsson H. Routine Fecal Occult Blood Screening and Colorectal Cancer Mortality in Sweden. JAMA Netw Open. 2024; 7(2): e240516.

[42] Maucort-Boulch D, de Martel C, Franceschi S, Plummer M. Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwide. Int J Cancer. 2018; 142(12): 2471-7.

[43] Liu Y, Chang CC, Marsh GM, Wu F. Population attributable risk of aflatoxin-related liver cancer: systematic review and meta-analysis. Eur J Cancer. 2012; 48(14): 2125-36.

[44] Rumgay H, Arnold M, Ferlay J, Lesi O, Cabasag CJ, Vignat J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022; 77(6): 1598-606.

[45] Sun Y, Wang Y, Li M, Cheng K, Zhao X, Zheng Y, et al. Long-term trends of liver cancer mortality by gender in urban and rural areas in China: an age-period-cohort analysis. BMJ Open. 2018; 8(2): e020490.

[46] Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023; 77(4): 1335-47.

[47] Huang DQ, Singal AG, Kono Y, Tan DJH, El-Serag HB, Loomba R. Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. Cell Metab. 2022; 34(7): 969-77. e2.

[48] Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018; 391(10125): 1023-75.

[49] Klein AP. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol. 2021; 18(7): 493-502.

[50] Wood LD, Canto MI, Jaffee EM, Simeone DM. Pancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment. Gastroenterology. 2022; 163(2): 386-402. e1.

[51] Yang J, Xu R, Wang C, Qiu J, Ren B, You L. Early screening and diagnosis strategies of pancreatic cancer: a comprehensive review. Cancer Commun (Lond). 2021; 41(12): 1257-74.

RIGHTS & PERMISSIONS

2025 The Author(s). Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat-sen University Cancer Center.